Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer.

References

• Du Y, Zhou L, Wang Y, et al. Association of alpha2a and beta2 adrenoceptor expression with clinical outcome in breast cancer. Curr Med Res Opin 2014: published online 21 March 2014
   Google Scholar
• Patanè S. Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies. J Card Fail 2014;20:456-7
   Google Scholar
• Patanè S. Cardiotoxicity: cisplatin and long term cancer survivors. Int J Cardiol 2014: published online 29 April 2014, doi: 10.1016/j.ijcard.2014.04.238
   Google Scholar
• Patanè S. A challenge in cardiology: the oncosurgery. Int J Cardiol 2014: published online 13 April 2014, doi: 10.1016/j.ijcard.2014.04.046
   Google Scholar
• Seicean S, Seicean A, Alan N, et al. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 2013;6:420-6
   PubMed Web of Science ®Google Scholar
• Kafetzopoulou LE, Boocock DJ, Dhondalay GK, et al. Biomarker identification in breast cancer: Beta-adrenergic receptor signaling and pathways to therapeutic response. Comput Struct Biotechnol J 2013;6:e201303003
   PubMedGoogle Scholar
• Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 2010;1:466-9
   PubMedGoogle Scholar
• Francis SA, Cheng S, Arteaga CL, Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment. J Am Heart Assoc 2014;3:e000780
   PubMed Web of Science ®Google Scholar
• Lindgren ME, Fagundes CP, Alfano CM, et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology 2013;22:1889-94
   PubMed Web of Science ®Google Scholar
• Obeid EI, Conzen SD. The role of adrenergic signaling in breast cancer biology. Cancer Biomark 2013;13:161-9
   PubMed Web of Science ®Google Scholar
• Ganz PA, Habel LA, Weltzien EK, et al. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549-56
   PubMed Web of Science ®Google Scholar
• Sørensen GV, Ganz PA, Cole SW, et al. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 2013;31:2265-72
   PubMed Web of Science ®Google Scholar
• Cardwell CR, Coleman HG, Murray LJ, et al. Beta-blocker usage and breast cancer survival: a nested case–control study within a UK Clinical Practice Research Datalink cohort. Int J Epidemiol 2013;42:1852-61
   PubMed Web of Science ®Google Scholar
• Pérez Piñero C, Bruzzone A, Sarappa MG, et al. Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol 2012;166:721-36
   PubMed Web of Science ®Google Scholar
• Lüthy IA, Bruzzone A, Piñero CP, et al. Adrenoceptors: non conventional target for breast cancer? Curr Med Chem 2009;16:1850-62
   PubMed Web of Science ®Google Scholar
• Staudacher I, Jehle J, Staudacher K, et al. HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One 2014;9:e88164
   PubMed Web of Science ®Google Scholar
• Bruzzone A, Piñero CP, Rojas P, et al. α(2)-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets 2011;11:763-74
   PubMed Web of Science ®Google Scholar
• Petty A, Myshkin E, Qin H, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One 2012;7:e42120
   PubMed Web of Science ®Google Scholar
• El Sharkawi FZ, El Shemy HA, Khaled HM. Possible anticancer activity of rosuvastatine, doxazosin, repaglinide and oxcarbazepin. Asian Pac J Cancer Prev 2014;15:199-203
   PubMed Web of Science ®Google Scholar
• Kammerer S, Sokolowski A, Hackl H, et al. 40p * overexpression of g protein-activated inward rectifier potassium channel 1 (girk1) is associated with lymph node metastasis and poor prognosis in breast cancer. Ann Oncol 2014;25(Suppl 1):i13-14
   Google Scholar
• Plummer HK 3rd, Yu Q, Cakir Y, Schuller HM. Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer 2004;4:93
   PubMed Web of Science ®Google Scholar
• von Bueren AO, Ma R, Schlumpf M, Lichtensteiger W. Salbutamol exhibits androgenic activity in vitro. Br J Sports Med 2007;41:874-8, discussion 878
   Google Scholar
• Mahdian D, Shafiee-Nick R, Mousavi SH. Different effects of adenylyl cyclise activators and phosphodiesterases inhibitors on cervical cancer (HeLa) and breast cancer (MCF-7) cells proliferation. Toxicol Mech Methods 2014;24(4):307-14
   Google Scholar
• Clarysse L, Guéguinou M, Potier-Cartereau M, et al. cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex. Pflugers Arch 2014: published online 24 January 2014
   Google Scholar
• Patanè S. A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis. Int J Cardiol 2012;157:448-9
   PubMed Web of Science ®Google Scholar